ApcinteX

ApcinteX Develops and Markets Anticoagulant APC Pathway for Hemophilia Treatment. Apcintex has developed a new treatment method aimed at reducing the activity of a key natural anticoagulant pathway to induce normal blood clotting in hemophilia patients. This means the drug has the potential to treat all types of hemophilia patients, including those who have developed antibodies against replacement factors. Additionally, the drug does not induce the formation of anticoagulant antibodies and can be administered via a simple subcutaneous injection once every two weeks.